Enteromac makes an action similar to action of bacitracin 50%
which targets primarily gram-positive bacteria, including Streptococci, Staphylococci, – Clostridia, Fusobacterium and Actinomyces.
Bacitracin interferes with protein synthesis and cell wall production and induces cell lysis in microorganisms.
Indication:
Enteromac treats and prevents necrotic enteritis caused by Clostridium perfringen.
Enteromac Improves growth rate and feed utilization by broiler chickens enteromac Improves gastrointestinal tract and regulate internal environment of GIT.
Enteromac improves the structure and histomorphology of the intestinal mucosa and enhances absorption capacity.
Enteromac improves immune system and systemic metabolism of minerals and lipids.
Enteromac enhances intestinal micro biota through favoring quick proliferation of beneficial bifidbacterium and lactobacillus strains.
